ID   ST2A1_RAT               Reviewed;         284 AA.
AC   P15709; A0A0G2JYC0;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   02-DEC-2020, sequence version 4.
DT   24-JAN-2024, entry version 154.
DE   RecName: Full=Sulfotransferase 2A1;
DE            Short=ST2A1;
DE            EC=2.8.2.2 {ECO:0000250|UniProtKB:Q06520};
DE   AltName: Full=Bile salt sulfotransferase;
DE            EC=2.8.2.14 {ECO:0000250|UniProtKB:Q06520};
DE   AltName: Full=Hydroxysteroid sulfotransferase {ECO:0000303|PubMed:2590219};
DE            Short=ST {ECO:0000303|PubMed:2590219};
DE   AltName: Full=ST-20;
GN   Name=Sult2a1; Synonyms=St2a1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], DEVELOPMENTAL STAGE, AND SUBCELLULAR LOCATION.
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=2590219; DOI=10.1016/0006-291x(89)91050-4;
RA   Ogura K., Kajita J., Narihata H., Watabe T., Ozawa S., Nagata K.,
RA   Yamazoe Y., Kato R.;
RT   "Cloning and sequence analysis of a rat liver cDNA encoding hydroxysteroid
RT   sulfotransferase.";
RL   Biochem. Biophys. Res. Commun. 165:168-174(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=8033273; DOI=10.1016/0009-2797(94)90056-6;
RA   Watabe T., Ogura K., Satsukawa M., Okuda H., Hiratsuka A.;
RT   "Molecular cloning and functions of rat liver hydroxysteroid
RT   sulfotransferases catalysing covalent binding of carcinogenic polycyclic
RT   arylmethanols to DNA.";
RL   Chem. Biol. Interact. 92:87-105(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [4]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=7854148; DOI=10.1093/mutage/9.6.553;
RA   Glatt H., Seidel A., Harvey R.G., Coughtrie M.W.;
RT   "Activation of benzylic alcohols to mutagens by human hepatic
RT   sulphotransferases.";
RL   Mutagenesis 9:553-557(1994).
CC   -!- FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate
CC       (PAPS) as sulfonate donor to catalyze the sulfonation of steroids and
CC       bile acids in the liver and adrenal glands (By similarity). Mediates
CC       the sulfation of a wide range of steroids and sterols, including
CC       pregnenolone, androsterone, DHEA, bile acids, cholesterol and as well
CC       many xenobiotics that contain alcohol and phenol functional groups
CC       (PubMed:7854148). Sulfonation increases the water solubility of most
CC       compounds, and therefore their renal excretion, but it can also result
CC       in bioactivation to form active metabolites. Plays an important role in
CC       maintening steroid and lipid homeostasis. Plays a key role in bile acid
CC       metabolism (By similarity). In addition, catalyzes the metabolic
CC       activation of potent carcinogenic polycyclic arylmethanols
CC       (PubMed:7854148). {ECO:0000250|UniProtKB:Q06520,
CC       ECO:0000269|PubMed:7854148}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-phosphoadenylyl sulfate + an alcohol = adenosine 3',5'-
CC         bisphosphate + an alkyl sulfate + H(+); Xref=Rhea:RHEA:22552,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30879, ChEBI:CHEBI:58339,
CC         ChEBI:CHEBI:58343, ChEBI:CHEBI:83414; EC=2.8.2.2;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:22553;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-phosphoadenylyl sulfate + taurolithocholate = adenosine
CC         3',5'-bisphosphate + H(+) + taurolithocholate 3-sulfate;
CC         Xref=Rhea:RHEA:14013, ChEBI:CHEBI:15378, ChEBI:CHEBI:17179,
CC         ChEBI:CHEBI:58301, ChEBI:CHEBI:58339, ChEBI:CHEBI:58343; EC=2.8.2.14;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:14014;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-phosphoadenylyl sulfate + lithocholate = adenosine 3',5'-
CC         bisphosphate + H(+) + lithocholate sulfate; Xref=Rhea:RHEA:51064,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29744, ChEBI:CHEBI:58339,
CC         ChEBI:CHEBI:58343, ChEBI:CHEBI:133940;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:51065;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(24S)-hydroxycholesterol + 3'-phosphoadenylyl sulfate = (24S)-
CC         hydroxycholesterol 24-sulfate + adenosine 3',5'-bisphosphate + H(+);
CC         Xref=Rhea:RHEA:52344, ChEBI:CHEBI:15378, ChEBI:CHEBI:34310,
CC         ChEBI:CHEBI:58339, ChEBI:CHEBI:58343, ChEBI:CHEBI:136566;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52345;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(24S)-hydroxycholesterol + 3'-phosphoadenylyl sulfate = (24S)-
CC         hydroxycholesterol 3-sulfate + adenosine 3',5'-bisphosphate + H(+);
CC         Xref=Rhea:RHEA:52348, ChEBI:CHEBI:15378, ChEBI:CHEBI:34310,
CC         ChEBI:CHEBI:58339, ChEBI:CHEBI:58343, ChEBI:CHEBI:136567;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52349;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(24S)-hydroxycholesterol 24-sulfate + 3'-phosphoadenylyl
CC         sulfate = (24S)-hydroxycholesterol 3,24-disulfate + adenosine 3',5'-
CC         bisphosphate + H(+); Xref=Rhea:RHEA:52352, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:58339, ChEBI:CHEBI:58343, ChEBI:CHEBI:136566,
CC         ChEBI:CHEBI:136568; Evidence={ECO:0000250|UniProtKB:Q06520};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52353;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-phosphoadenylyl sulfate + 3beta-hydroxyandrost-5-en-17-one
CC         = adenosine 3',5'-bisphosphate + dehydroepiandrosterone 3-sulfate +
CC         H(+); Xref=Rhea:RHEA:51216, ChEBI:CHEBI:15378, ChEBI:CHEBI:28689,
CC         ChEBI:CHEBI:57905, ChEBI:CHEBI:58339, ChEBI:CHEBI:58343;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:51217;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-phosphoadenylyl sulfate + pregnenolone = adenosine 3',5'-
CC         bisphosphate + H(+) + pregnenolone sulfate; Xref=Rhea:RHEA:52356,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16581, ChEBI:CHEBI:58339,
CC         ChEBI:CHEBI:58343, ChEBI:CHEBI:133000;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52357;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-phosphoadenylyl sulfate + androsterone = adenosine 3',5'-
CC         bisphosphate + androsterone 3alpha-sulfate + H(+);
CC         Xref=Rhea:RHEA:60644, ChEBI:CHEBI:15378, ChEBI:CHEBI:16032,
CC         ChEBI:CHEBI:58339, ChEBI:CHEBI:58343, ChEBI:CHEBI:133003;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:60645;
CC         Evidence={ECO:0000250|UniProtKB:Q06520};
CC   -!- SUBUNIT: Homodimer. {ECO:0000250|UniProtKB:Q06520}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:2590219}.
CC   -!- DEVELOPMENTAL STAGE: There is a marked sex difference (female >> male)
CC       in the expressed level of mRNA for this protein.
CC       {ECO:0000269|PubMed:2590219}.
CC   -!- INDUCTION: Induced by estrogens and suppressed by androgens. Expression
CC       is under the influence of pituitary growth hormone and thyroid hormone.
CC   -!- SIMILARITY: Belongs to the sulfotransferase 1 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M31363; AAA41356.1; -; mRNA.
DR   EMBL; D14988; BAA03633.1; -; mRNA.
DR   EMBL; D14987; BAA03632.1; -; mRNA.
DR   EMBL; AABR07002517; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07002526; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07002525; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07002524; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07002523; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07002522; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07002521; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07002520; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07002519; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07002518; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   PIR; A33569; A33569.
DR   PIR; I52849; I52849.
DR   RefSeq; NP_571978.1; NM_131903.1.
DR   RefSeq; XP_008757114.1; XM_008758892.2.
DR   AlphaFoldDB; P15709; -.
DR   SMR; P15709; -.
DR   BindingDB; P15709; -.
DR   ChEMBL; CHEMBL3007; -.
DR   iPTMnet; P15709; -.
DR   PhosphoSitePlus; P15709; -.
DR   PaxDb; 10116-ENSRNOP00000043445; -.
DR   GeneID; 24912; -.
DR   KEGG; rno:24912; -.
DR   UCSC; RGD:621337; rat.
DR   AGR; RGD:621337; -.
DR   CTD; 6822; -.
DR   RGD; 621337; Sult2a1.
DR   eggNOG; KOG1584; Eukaryota.
DR   InParanoid; P15709; -.
DR   OrthoDB; 3083090at2759; -.
DR   PhylomeDB; P15709; -.
DR   Reactome; R-RNO-156584; Cytosolic sulfonation of small molecules.
DR   Reactome; R-RNO-9753281; Paracetamol ADME.
DR   PRO; PR:P15709; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000047986; Expressed in liver and 16 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0050656; F:3'-phosphoadenosine 5'-phosphosulfate binding; IDA:RGD.
DR   GO; GO:0004027; F:alcohol sulfotransferase activity; IDA:RGD.
DR   GO; GO:0047704; F:bile-salt sulfotransferase activity; ISS:UniProtKB.
DR   GO; GO:0050294; F:steroid sulfotransferase activity; ISS:UniProtKB.
DR   GO; GO:0008146; F:sulfotransferase activity; IDA:RGD.
DR   GO; GO:0016740; F:transferase activity; IDA:RGD.
DR   GO; GO:0050427; P:3'-phosphoadenosine 5'-phosphosulfate metabolic process; ISO:RGD.
DR   GO; GO:0071305; P:cellular response to vitamin D; IDA:RGD.
DR   GO; GO:0008203; P:cholesterol metabolic process; ISS:UniProtKB.
DR   GO; GO:0006068; P:ethanol catabolic process; ISO:RGD.
DR   GO; GO:0014823; P:response to activity; IEP:RGD.
DR   GO; GO:0017085; P:response to insecticide; IEP:RGD.
DR   GO; GO:0031667; P:response to nutrient levels; IEP:RGD.
DR   GO; GO:0008202; P:steroid metabolic process; IDA:RGD.
DR   GO; GO:0051923; P:sulfation; IDA:RGD.
DR   GO; GO:0042403; P:thyroid hormone metabolic process; ISO:RGD.
DR   GO; GO:0006805; P:xenobiotic metabolic process; IDA:RGD.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000863; Sulfotransferase_dom.
DR   PANTHER; PTHR11783:SF8; SULFOTRANSFERASE 2A1; 1.
DR   PANTHER; PTHR11783; SULFOTRANSFERASE SULT; 1.
DR   Pfam; PF00685; Sulfotransfer_1; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
PE   1: Evidence at protein level;
KW   Cytoplasm; Lipid metabolism; Reference proteome; Steroid metabolism;
KW   Transferase.
FT   CHAIN           1..284
FT                   /note="Sulfotransferase 2A1"
FT                   /id="PRO_0000085144"
FT   ACT_SITE        98
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         43
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         44
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         45
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         46
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         47
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         48
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         120
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         128
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         183
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         217
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         222
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         246
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         247
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   BINDING         248
FT                   /ligand="3'-phosphoadenylyl sulfate"
FT                   /ligand_id="ChEBI:CHEBI:58339"
FT                   /evidence="ECO:0000250|UniProtKB:Q06520"
FT   CONFLICT        33
FT                   /note="D -> E (in Ref. 2; BAA03633/BAA03632)"
FT   CONFLICT        81..85
FT                   /note="LGYDM -> VGYDI (in Ref. 1; AAA41356 and 2; BAA03633/
FT                   BAA03632)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        95
FT                   /note="I -> M (in Ref. 1; AAA41356 and 2; BAA03633/
FT                   BAA03632)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        119
FT                   /note="V -> I (in Ref. 2; BAA03633/BAA03632)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        139
FT                   /note="A -> V (in Ref. 2; BAA03633/BAA03632)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        173
FT                   /note="R -> Q (in Ref. 1; AAA41356)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        242
FT                   /note="I -> T (in Ref. 1; AAA41356)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        250
FT                   /note="V -> I (in Ref. 2; BAA03633/BAA03632)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   284 AA;  33135 MW;  9572B11D992DB0C4 CRC64;
     MPDYTWFEGI PFHAFGISKE TLQNVCNKFV VKDEDLILLA YPKSGTNWLI EIVCLIQTKG
     DPKWIQSVTI WDRSPWIETD LGYDMLIKKK GPRLITSHLP MHLFSKSLFS SKAKVIYLVR
     NPRDVLVSGY YFWGNSTLAK KPDSLGTYVE WFLKGNVLYG SWFEHIRAWL SMREWDNFLL
     LYYEDMKKDT MGTIKKICDF LGKKLEPDEL DLVLKYSSFQ VMKENDMSNY SLLMKKSIFT
     GIGLMRKGTV GDWKNHFTVS QAEAFDKVFQ EKMAGFPPGM FPWE
//
